Common and Not-So-Common Comorbidities of Psoriasis
The prevalence of suicidality among patients with psoriasis can be as high as 37.4% during a lifetime vs 1.01% to 1.94% among the general population, with two-thirds of patients attributing their suicidal ideation to their psoriasis.21,22 Data are conflicting about whether there is a dose-response relationship between psoriasis severity and suicide.21 Clearly, however, comorbid depression confers greater risk for suicide among patients with psoriasis than does severity of the disease alone. In one UK study, major depression contributed to a 10-fold risk for suicide among patients with psoriasis.21
Appropriate treatment of psoriasis can ameliorate comorbid depression and anxiety.21 Papp and colleagues23 reported significant decreases in depression and anxiety, as measured by the Hospital Anxiety and Depression Scale (HADS), in patients treated with brodalumab 140 mg (n=219) or 210 mg (n=222) every 2 weeks, compared with patients who received placebo (n=220; P<0.0001 for brodalumab 140 or 210 mg vs placebo). Researchers also found that the TNF inhibitor adalimumab simultaneously decreased the Psoriasis Area and Severity Index (PASI) scores of >75% of patients studied and improved scores for depression (P<0.001).24
Opportunistic infections are a frequent adverse effect associated with TNF-alpha inhibitors. One study, for example, reported that the rate of serious infection was 4.02 per 100 patient-years (95% CI, 3.20-5.04).25 Gastrointestinal infections were the most common, followed by tuberculosis, extrapulmonary infections, and malignancies.25 Infections are also a concern with the newer biologics. In a phase 3 trial of secukinumab, a human anti–IL-17A monoclonal antibody, the most common adverse event was upper respiratory tract infection.26 At minimum, clinicians ought to screen patients every 3 months for infection, at least initially.
New Treatment Paradigms in Psoriasis: Understanding and Incorporating Recent and Emerging Trends
This journal supplement is intended for dermatologists, residents, internists, primary care practitioners, registered nurses, nurse practitioners, and physi- cian assistants who treat patients with psoriasis.
Supported by an educational grant from:
Ortho Dermatologics
Activity Information
EXPIRED
Original Release Date: March 2018
Expiration Date: April 30, 2019
Estimated Time to Complete Activity: 2.0 hours
EXPIRED
Participants should read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via e-mail or you may print it out at that time.The online post-test and evaluation can be accessed at https://tinyurl.com/Psoriasis2018.
Inquiries about CME accreditation may be directed to the University of Louisville Office of Continuing Medical Education & Professional Development (CME & PD) at cmepd@louisville.edu or 502-852-5329.
Faculty
![]() | M. Alan Menter, MD, Chair |
![]() | April W. Armstrong, MD, MPH |
![]() | Kenneth B. Gordon, MD |
![]() | Jashin J. Wu, MD |
CME/CE Accreditation Statements
Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville and Global Academy for Medical Education, LLC. The University of Louisville is accredited by the ACCME to provide continuing education for physicians.
The University of Louisville Office of Continuing Medical Education & Professional Development designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Global Academy for Medical Education.
Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Designated for 0.8 contact hours of pharmacotherapy credit for Advance Practice Nurses.
Educational Needs
Psoriasis—a chronic, inflammatory, immune-system disease that affects approximately 8 million Americans—is often underdiagnosed. Many clinicians do not approach psoriasis as a systemic, immune-mediated disease with multiple comorbidities, including obesity, metabolic syndrome, cardiovascular disease, and psoriatic arthritis. Even though half of patients with psoriasis complain of arthritic pain, for example, more than two-thirds of dermatologists lack confidence in screening for arthritic comorbidities. Clinicians also frequently fail to screen patients with psoriasis for cardiovascular risk factors, in part because they are unaware that the presence of psoriasis is associated with poor CV outcomes.
Psoriasis is often undertreated. One recent survey found that two-thirds of patients with psoriasis reported being dissatisfied with their treatment; many discontinue treatment due to a lack of efficacy or because of adverse effects. Many clinicians fail to select a therapeutic option that addresses the needs of individual patients, and many neglect the importance of counseling patients adequately about the optimal use of medications or about what to expect from treatment. Complicating the situation is the fact that many clinicians do not adopt a treat-to-target strategy that establishes clear therapeutic goals based on treatment severity (including addressing quality-of-life issues) and that calls for adjusting the regimen as needed.
Clinicians would benefit from education that describes the growing armamentarium of available agents for the treatment of psoriasis, explains the importance of identifying and managing common comorbidities of psoriasis, and presents current data on designing and deploying a treat-to-target strategy, including the use of topical agents and biologics, alone or in combination.
Learning Objectives
By reading and studying this supplement, participants should be better able to:
- Explain the etiology and pathophysiology of psoriasis and its common comorbidities
- Diagnoseandtreatpatientswithpsoriasisusingtreat-to-targetguidelines
- Selectappropriatebiologictherapiesforpatientswithpsoriasis
Disclosure Declarations
Individuals in a position to control the content of this educational activity are required to disclose: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/ device not yet approved.
April W. Armstrong, MD, MPH, Consultant: AbbVie Inc., Amgen Inc., Eli Lilly and Company, Janssen Biotech, Inc., Modernizing Medicine, Novartis Pharmaceuticals Corporation, Regeneron, Sanofi. Speakers Bureau: AbbVie Inc., Eli Lilly and Company, Janssen Biotech, Inc.
Kenneth B. Gordon, MD, Consultant: AbbVie Inc., Amgen Inc., Almirall, S.A., Boehringer Ingelheim, Bristol Myers-Squibb Company, Celgene Corporation, Dermira,Inc.,Eli Lilly and Company, LEO Pharma Inc.,Novartis Pharmaceuticals Corporation, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB, Inc. Investigator: AbbVie Inc., Boehringer Ingelheim, Celgene Corporation, Novartis Pharmaceuticals Corporation.
M. Alan Menter, MD, Advisory Board: AbbVie Inc., Afecta Pharmaceuticals, Inc., Amgen Inc., Boehringer Ingelheim, Eli Lilly and Company, Janssen Biotech, Inc., LEO Pharma Inc., Ortho Dermatologics, Promius Pharma, LLC. Consultant: AbbVie Inc., Afecta Pharmaceuticals, Inc., Amgen Inc., Avillion LLP, Boehringer Ingelheim, Eli Lilly and Company, Galderma S.A., Janssen Biotech, Inc., LEO Pharma Inc., Menlo Therapeutics Inc., Novartis Pharmaceuticals Corporation, Ortho Dermatologics, Pfizer Inc., Promius Pharma, LLC. Investigator: AbbVie Inc., Amgen Inc., Boehringer Ingelheim, Celgene Corporation, Dermira, Inc., Eli Lilly and Company, Janssen Biotech, Inc., LEO Pharma Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron. Speakers Bureau: AbbVie Inc., Amgen Inc., Janssen Biotech, Inc., LEO Pharma Inc., Ortho Dermatologics, Promius Pharma, LLC.
Jashin J. Wu, MD, Contracted Research: AbbVie Inc., Amgen Inc., Eli Lilly and Company, Janssen Biotech, Inc., Novartis Pharmaceuticals Corporation, Regeneron.
University of Louisville CME & PD Advisory Board and Staff Disclosures: The CME & PD Advisory Board and Staff have nothing to disclose.
CME/CE Reviewers: Timothy S. Brown, MD, Clinical Associate Professor, Division of Dermatology, Department of Medicine, University of Louisville School of Medicine. The Postgraduate Institute of Medicine planners and managers Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
Global Academy for Medical Education Staff: Suzanne Bujara; Tristan M. Nelsen, MNM, CMP, HMCC; Sylvia H. Reitman, MBA, DipEd; and Ron Schaumburg have nothing to disclose.
Off-Label/Investigational Use Disclosure
This CME/CE activity discusses the off-label use of certain approved medications as well as data from clinical trials on investigational agents. Such material is identified within the text of the articles.
This continuing medical education (CME/CE) supplement was developed from interviews with the faculty. The Guest Editors acknowledge the editorial assistance of Global Academy for Medical Education and Suzanne Bujara, medical writer, in the development of this supplement. The manuscript was reviewed and approved by the guest editors as well as the Editors of Seminars in Cutaneous Medicine and Surgery. The ideas and opinions expressed in this supplement are those of the Guest Editors and do not necessarily reflect the views of the supporter, Global Academy for Medical Education, University of Louisville, Postgraduate Institute for Medicine, or the publisher.
References
- National Psoriasis Foundation. About psoriatic arthritis. https://www.psoriasis.org/about- psoriatic-arthritis. Accessed January 17, 2018.
- Helliwell PS. Psoriasis Epidemiology Screening Tool (PEST): A report from the GRAPPA 2009 annual meeting. J Rheumatol. 2011;38:551-552.
- Chandran V, Gladman DD. Toronto Psoriatic Arthritis Screening (ToPAS) questionnaire: A report from the GRAPPA 2009 annual meeting. J Rheumatol. 2011;38:546-547.
- Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: Pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57:581-587.
- Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 2006;54: 685-704.
- Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol. 2007;57:347-354.
- Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-1741.
- Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: Results from a population-based study. Arch Dermatol. 2007;143:1493-1499.
- Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol. 2008;159 (suppl 2):2-9.
- Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428. 11.
- Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res.2006;298:321-328.
- Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patientswith psoriasis: A population-based study in the United Kingdom. J Invest Dermatol.2012;132:556-562.
- Danielsen K, Wilsgaard T, Olsen AO, Furberg AS. Overweight and weight gain predict psori- asis development in a population-based cohort. Acta Derm Venereol. 2017;97:332-339.
- Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: An update. Clin Endocrinol (Oxf). 2006;64:355-365.
- Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: A systematic review and meta-analysis. JAMA Dermatol. 2013;149:84-91.
- Mansouri B, Kivelevitch D, Natarajan B, et al. Comparison of coronary artery calcium scores between patients with psoriasis and type 2 diabetes. JAMA Dermatol. 2016;152:1244-1253.
- Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am AcadDermatol. 2005;52:262-267.
- Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244-1250.
- Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: A Danish real-world cohort study. J Intern Med. 2013;273:197-204.
- Wu JJ, Guérin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76:81-90.
- Wu JJ, Feldman SR, Koo J, Marangell LB. Epidemiology of mental health comorbidity in psoriasis [published online November 10, 2017]. Dermatolog Treat. 2017;1-9. doi:10.1080/095 46634.2017.1395800.
- Wu JJ, Penfold RB, Primatesta P, et al. The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. J Eur Acad Dermatol Venereol. 2017;31:1168-1175.
- PappKA, ReichK, PaulC, etal. Aprospective phase III, randomized, double-blind, placebo- controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273-286.
- Menter A, Augustin M, Signorovitch J, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial. J Am Acad Dermatol. 2010;62:812-818.
- Pereira R, Faria R, Lago P, Torres T, et al. Infection and malignancy risk in patients treated with TNF inhibitors for immune-mediated inflammatory diseases. Curr Drug Saf. 2017;12:162-170.
- McInnes IB, Mease PJ, Kirkham B, et al; FUTURE 2 Study Group. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137-1146.
- Patruno C, Napolitano M, Balato N, et al. Psoriasis and skin pain: Instrumental and biological evaluations. Acta Derm Venereol. 2015;95:432-438.
- Viswanathan HN, Mutebi A, Milmont CE, et al. Measurement properties of the Psoriasis Symptom Inventory electronic daily diary in patients with moderate to severe plaque psoriasis. Value Health. 2017;20:1174-1179.
- Puig L, Augustin M, Blauvelt A, et al. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study [published online October 21, 2017]. J Am Acad Dermatol. doi:10.1016/j. jaad.2017.10.025.
- Eppinga H, Poortinga S, Thio HB, et al. Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1783-1789.
- WenZ, FiocchiC. Inflammatory bowel disease: Auto immune orimmune-mediatedpathogenesis? Clin Dev Immunol. 2004;11:195-204.
- OussedikE,PatelNU, CashDR, GuptaAS, FeldmanSR. Severe and acute complications of biologics in psoriasis. G Ital Dermatol Venereol. 2017;152:586-596.
- Amin M, Darji K, No DJ, Bhutani T, Wu JJ. Review of IL-17 inhibitors for psoriasis [published online November 10, 2017]. J Dermatolog Treat. 2017:1-6. doi:10.1080/09546634.2 017.1395796.
- Roberts KK, Cochet AE, Lamb PB, et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther. 2015;41:293-300.
- Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: A population-based study. JAMA Dermatol. 2013;149:1173-1179.
- Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76:377-390.
- Nguyen UDT, Zhang Y, Lu N, et al. Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: A population-based study. Ann Rheum Dis. 2018;77:119-123.
- Lee EJ, Han KD, Han JH, Lee JH. Smoking and risk of psoriasis: A nationwide cohort study. J Am Acad Dermatol. 2017;77:573-575.
- Afifi L, Danesh MJ, Lee KM, et al. Dietary behaviors in psoriasis: Patient-reported outcomes from a U.S. national survey. Dermatol Ther (Heidelb). 2017;7:227-242.
- Parisi R, Webb RT, Carr MJ, et al. Alcohol-related mortality in patients with psoriasis: A population-based cohort study. JAMA Dermatol. 2017;153:1256-1262.
Disclosures
*Chairman, Division of Dermatology, Baylor University Medical Center, Dallas, Texas
† Associate Professor of Clinical Dermatology, Associate Dean for Clinical Research, Keck School of Medicine of the University of Southern California, Los Angeles, California
‡ Professor and Chair, Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin
§ Director of Dermatology Research, Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California
Publication of this CME/CE article was jointly provided by University of Louisville, Postgraduate Institute for Medicine, and Global Academy for Medical Education, LLC, and is supported by an educational grant from Ortho Dermatologics. The authors have received an honorarium for their participation in this activity. They acknowledge the editorial assistance of Suzanne Bujara, medical writer, and Global Academy for Medical Education in the development of this continuing medical education journal article.
M. Alan Menter, MD, Advisory Board: AbbVie Inc., Afecta Pharmaceuticals, Inc., Amgen Inc., Boehringer Ingelheim, Eli Lilly and Company, Janssen Biotech, Inc., LEO Pharma Inc., Ortho Dermatologics, Promius Pharma, LLC. Consultant: AbbVie Inc., Afecta Pharmaceuticals, Inc., Amgen Inc., Avillion LLP, Boehringer Ingelheim, Eli Lilly and Company, Galderma S.A., Janssen Biotech, Inc., LEO Pharma Inc., Menlo Therapeutics Inc., Novartis Pharmaceuticals Corporation, Ortho Dermatologics, Pfizer Inc., Promius Pharma, LLC. Investigator: AbbVie Inc., Amgen Inc., Boehringer Ingelheim, Celgene Corporation, Dermira, Inc., Eli Lilly and Company, Janssen Biotech, Inc., LEO Pharma Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron. Speakers Bureau: AbbVie Inc., Amgen Inc., Janssen Biotech, Inc., LEO Pharma Inc., Ortho Dermatologics, Promius Pharma, LLC.
April W. Armstrong, MD, MPH, Consultant: AbbVie Inc., Amgen Inc., Eli Lilly and Company, Janssen Biotech, Inc., Modernizing Medicine, Novartis Pharmaceuticals Corporation, Regeneron, Sanofi. Speakers Bureau: AbbVie Inc., Eli Lilly and Company, Janssen Biotech, Inc.
Kenneth B. Gordon, MD, Consultant: AbbVie Inc., Amgen Inc., Almirall, S.A., Boehringer Ingelheim, Bristol Myers-Squibb Company, Celgene Corporation, Dermira, Inc., Eli Lilly and Company, LEO Pharma Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB, Inc. Investigator: AbbVie Inc., Boehringer Ingelheim, Celgene Corporation, Novartis Pharmaceuticals Corporation.
Jashin J. Wu, MD, Contracted Research: AbbVie Inc., Amgen Inc.,
Eli Lilly and Company, Janssen Biotech, Inc., Novartis Pharmaceuticals Corporation, Regeneron.
Address reprint requests to: Address reprint requests to: M. Alan Menter, MD, 3900 Junius Street, Suite 145, Dallas, TX 75246; amderm@gmail.com
1085-5629/13/$-seefrontmatter ©2018FrontlineMedicalCommunications doi:10.12788/j.sder.2018.011